Abstract
Background: Under certain circumstances, the path for protein folding deviates and attains an alternative path forming misfolded states, which are the key precursors for protein aggregation. Protein aggregation is associated with variety of diseases and leads to the cytotoxicity. These protein aggregate related diseases have been untreated so far. However, extensive attempts have been applied to develop anti-aggregating agents as possible approaches to overcome protein aggregation. Different types of substances have been reported to halt or decrease the formation of ordered protein aggregates both in vitro and in vivo, such as polyphenols and metal ions.
Objective: In the present study the in vitro aggregation of human serum albumin (HSA) by using a reactive dicarbonyl glyoxal has been investigated, simultaneously an attempt has been done to inhibit the glyoxal (GO) induced aggregation of (HSA) by caffeic acid (CA).
Methods: Different methods have been employed to investigate the process, fluorescence spectroscopy, circular dichroism, cango red binding assay, thioflavin T dye binding, turbidimetric analysis, docking study and transmission electron microscopy.
Results: Results have shown that elevated concentration of GO forms aggregates of HSA, and the activity of CA suggested the possibility of inhibiting the HSA aggregation at higher concentrations, and this compound was found to have an anti-aggregation property.
Conclusion: The present study explained that micro molar concentrations of CA inhibits the aggregation of HSA and showed pronounced anti-aggregation effect at increasing concentrations in the presence of GO which is elevated in diabetic and hyperglycaemia conditions.
Keywords: Aggregation, human serum albumin, glyoxal, glycation, caffeic acid, hyperglycaemia.
Graphical Abstract
[http://dx.doi.org/10.1016/j.ijbiomac.2013.11.010] [PMID: 24291768]
[http://dx.doi.org/10.1016/j.ijbiomac.2015.07.052] [PMID: 26231329]
[http://dx.doi.org/10.1038/nm1113] [PMID: 15459709]
[http://dx.doi.org/10.1080/07391102.2015.1108232] [PMID: 26555198]
[http://dx.doi.org/10.1016/j.ijbiomac.2016.08.082] [PMID: 27597744]
[http://dx.doi.org/10.1016/S0968-0896(99)00212-6] [PMID: 10632059]
[http://dx.doi.org/10.1016/j.biochi.2006.10.015] [PMID: 17175088]
[http://dx.doi.org/10.1002/pro.5560041120] [PMID: 8563639]
[http://dx.doi.org/10.1016/j.procbio.2017.03.021]
[http://dx.doi.org/10.1006/bbrc.1999.0221] [PMID: 10066428]
[http://dx.doi.org/10.1155/2012/819202] [PMID: 22567004]
[http://dx.doi.org/10.1016/j.cardiores.2004.05.001] [PMID: 15306213]
[http://dx.doi.org/10.1021/acs.chemrestox.5b00380] [PMID: 26517015]
[http://dx.doi.org/10.1081/JLC-100101786]
[http://dx.doi.org/10.1016/j.cplett.2007.12.018]